These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. Park SK; Park SH; Lee MY; Park JH; Jeong JH; Lee EK Clin Ther; 2016 Nov; 38(11):2430-2446.e3. PubMed ID: 27771177 [TBL] [Abstract][Full Text] [Related]
32. Massive intrahepatic hemorrhage following routine liver biopsy in a patient with rheumatoid arthritis treated with methotrexate. Cash JM; Swain M; Di Bisceglie AM; Wilder RL; Crofford LJ J Rheumatol; 1992 Sep; 19(9):1466-8. PubMed ID: 1433018 [TBL] [Abstract][Full Text] [Related]
33. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622 [TBL] [Abstract][Full Text] [Related]
34. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Walker AM; Funch D; Dreyer NA; Tolman KG; Kremer JM; Alarcón GS; Lee RG; Weinblatt ME Arthritis Rheum; 1993 Mar; 36(3):329-35. PubMed ID: 8452577 [TBL] [Abstract][Full Text] [Related]
35. Comparison of methods for identifying early methotrexate-induced hepatotoxicity in patients with rheumatoid arthritis. Arias JM; Morton KA; Albro JE; Patch GG; Valdivia S; Greenberg HE; Christian PE; Datz FL J Nucl Med; 1993 Nov; 34(11):1905-9. PubMed ID: 8229232 [TBL] [Abstract][Full Text] [Related]
36. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Kremer JM; Alarcón GS; Lightfoot RW; Willkens RF; Furst DE; Williams HJ; Dent PB; Weinblatt ME Arthritis Rheum; 1994 Mar; 37(3):316-28. PubMed ID: 8129787 [TBL] [Abstract][Full Text] [Related]
37. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany]. Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279 [TBL] [Abstract][Full Text] [Related]
38. Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease. Stephens S; Botteman MF; Cifaldi MA; van Hout BA BMJ Open; 2015 Jun; 5(6):e006560. PubMed ID: 26059521 [TBL] [Abstract][Full Text] [Related]
39. Creating a care-effective cost-effective strategy for methotrexate liver toxicity monitoring in rheumatoid arthritis: comment on the article by Kremer et al. Newman ED; Harrington TM; Perruquet JL; Davis DE; Torretti D Arthritis Rheum; 1995 Feb; 38(2):297-8. PubMed ID: 7848325 [No Abstract] [Full Text] [Related]
40. Assessment of Substantial Liver Fibrosis by Real-time Shear Wave Elastography in Methotrexate-Treated Patients With Rheumatoid Arthritis. Kim TY; Kim JY; Sohn JH; Lee HS; Bang SY; Kim Y; Kim MY; Jeong WK J Ultrasound Med; 2015 Sep; 34(9):1621-30. PubMed ID: 26269292 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]